Alpha Tau Medical Ltd
DRTS | NASDAQ
$15.50
+$0.26 (+1.71%)
At close: Sep 21, 2026, 4:00 PM ET
$15.19
-$0.31 (-1.98%)
Pre-market:
Sep 22, 2026, 8:07 AM ET
Company Profile
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer. Its Alpha-DaRT technology is in clinical trials for various forms comprising skin, oral, pancreatic, prostate, lung, liver, and breast cancers; and preclinical clinical studies for mouse tumors and human-derived tumors. The company is headquartered in Jerusalem, Israel.
Key Executives
| Name | Position |
|---|---|
| Uzi Sofer | Chief Executive Officer & Chairman |
| Raphi Levy | Chief Financial Officer |
| Ronen Segal | Chief Technology Officer |
| Amnon Gat | Chief Operations Officer |
| Rebecca Becker | Vice President of legal |
| Robert Den | Chief Medical Officer & Member of Scientific Advisory Board |
| Yael Zeiger | Corporate Controller |
| Yona Keisari | Chief Scientific Officer & Member of Scientific Advisory board |
Alpha Tau Medical Ltd
| Country | Israel |
| IPO Date | Mar 7, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 121 |
| CEO | Uzi Sofer |
Contact Details
Kiryat HaMada St. 5 Jerusalem,
JM 9777605 Israel
Stock Details
| Ticker Symbol | DRTS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001871321 |
| CUSIP Number | M0740A108 |
| ISIN Number | IL0011839383 |
| SIC Code | 3841 |
Recent News
- 11 days ago / seekingalpha.comOramed Pharmaceuticals: Hold Reiterated As Alpha Tau Investment Delivers And More
- 18 days ago / seekingalpha.comAlpha Tau: Approaching Massive Year-End; Pounding The Table On Potential GBM Breakthrough
- 20 days ago / globenewswire.comAlpha Tau to Participate in September Investor Conferences
- 22 days ago / globenewswire.comAlpha Tau Completes Patient Enrollment in its Multicenter IMPACT Pancreatic Cancer Pilot Study of Alpha DaRT® Following Strong Demand and Multiple Expansions
- 2 months ago / globenewswire.comAlpha Tau Reports Positive Data Demonstrating 100% Objective Response Rate and 18.2-Month Median Overall Survival with Alpha DaRT® in Combination with Pembrolizumab in Locally Advanced or Metastatic Head and Neck Cancer, Surpassing the Study's Pre-Specified Threshold for Success
Add to Watchlist
Select watchlists to add or remove DRTS